Dr. Eli Opper is the former Chief Scientist of the Ministry of Industry, Trade, and Labor in Israel (2002-2002-2011). Prior to his appointment as the Chief Scientist in May 2002, Dr. Opper was a Partner at Giza Venture Capital since 2000. Dr. Opper has held various senior positions at Rafael, Israel's leading defense systems developer including Vice President of Research and Development, Vice President of Advanced Topics, and General Manager of the Electronic Systems Division. Dr. Opper was also the former President of Europe’s Eureka R&D Fund. He has earned his Ph.D. degree in Computer Engineering from the University of Texas, Austin. Dr. Opper also received his B.Sc. and M.Sc. degrees in Electrical Engineering from the Technion.
Prof. Michel Revel, MD, PhD
Prof. Revel is Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. His research on Interferon, its mechanisms of action and the isolation of the human Interferon-beta gene, have led to the development of Interferon-beta therapy for the treatment of multiple sclerosis, Rebif®, Blockbuster drug marketed worldwide.
In recent years, Prof. Revel's laboratory focused on hESC and succeeded to produce nerve myelinating cells that, when transplanted in myelin-deficient animals, have regenerated the myelin coating. These studies contributed to the development of a suspension culture technology for hESC which can then be used to produce differentiated human cells such as insulin-producing pancreatic beta cells and nerve myelinating cells.
Alongside his research and development activity, Prof. Revel is deeply involved in the ethics of science and biotechnology, and serves as chairman of the Israel National Bioethics Council, and was a member of the International Bioethics Committee of UNESCO.
Prof. Revel was the recipient of the Israel Prize for medical research, the EMET Prize for biotechnology, and is a member of the Israel Academy of Science and Humanities. He has been a member of Israel's National Committee for Biotechnology, serving for three years as its chairman.
Mr. Ruggieri serves as Director of Monroe SA, a Luxembourg based investment company, wholly owned by the Batipart group (http://www.batipart.com). Before joining the Batipart Group, Mr. Ruggieri worked at Morgan Stanley Real Estate Funds (MSREF) in New York , after having worked for an American subsidiary of the Arcelor Mittal. He serves as the Chairman of the Board at Maelys SA, Fond Light Ltd. and Vice Chairman at Jardiland SA. He serves as a Member of Board of Directors at Proméo SA, Delta Car Trade SA and Onomo International SAS. He serves as a Representative Member of Supervisory Board at Korian SA. Mr. Ruggieri is a graduate of the European Business School and holds a DESS post-graduate degree in Audit from IAE, Aix-en-Provence and an MBA from the Johnson School at Cornell University.
Professor Joseph Itskovitz
Eldor - MD, DSc.
Professor Itskovitz-Eldor served as the head of the Obstetrics and Gynecology Department at Rambam Medical Center for 22 years, founded the Technion's embryonic stem cell center and is a professor emeritus at the Technion. In addition, Prof. Itskovitz-Eldor initiated the collaboration with James Thomson, of the University of Wisconsin in Madison, which derived the first human embryonic stem cells worldwide, and later in Israel as well.
In the research laboratories headed by Prof. Itskovitz-Eldor, the derivation of embryonic stem cells from a human source and their differentiation into various cell types was researched. Prof. Itskovitz-Eldor has published more than 200 scientific publications, in fields such as embryonic physiology, fertility medicine and pluripotent embryonic stem cells.
Rami Epstein, Adv.
Rami Epstein assumed the role of Chief Exective Officer of Kadimastem in May 2019, in addition to his role as a member of the Board of Directors, which he holds since 2013. Rami has over two decades of experience as an entrepreneur and business and legal counsel, mainly in the healthcare and high-tech industries. His main focus is on R&D companies, fund raising, M&As and strategic collaborations. Rami is co-founder of BiondVax Pharmaceuticals (Nasdaq: BVXV) and has served as a member of its Board of Directors for many years. Prior to founding BiondVax Rami co-founded IDgene Pharmaceuticals, and has served as the Company's Chief Operation Officer and as a member of its Board of Directors. Rami holds a master's degree (LL.M.) in commercial law and intellectual property from King's College, University of London, and a bachelor's degree (LL.B.) in law from the Hebrew University of Jerusalem.
Mr. Meizler is a leading figure in the pharmaceutical industry in South America in general, and in Brazil in particular. With a group of partners, Meizler recently invested in Nasvax Ltd. UCB is a partner in his company, Meizler UCB Biopharma. Meizler is also the joint owner of Advantech, which engages in the development and commercialization of biological drugs. Mr. Meizler is one of the largest private investors in Brainsway, whose products he distributes in Brazil. In addition, Mr. Meizler has invested in Therapix Bioscience and the life sciences company Nirolin.
Mr Sultan has 20 years of experience in the fields of operational business management, executive advisory and high tech investment operations. His resume includes senior positions at Disneyland Paris, Accenture, Rail Europe and more recently, in charge of new high tech opportunities scouting and analysis as Director of Magical Capital, helping corporates, funds and family offices looking to investing in high tech companies worldwide. He also leads a consulting activity, advising corporate leaders on structuring their business activity, organization and go to market. M. Sultan is a graduate of the EDHEC Business School in Lille, France.
Mrs. Keren-Blum is a lawyer and notary, the owner of Tzlill Keren-Blum Law Office. Mrs. Keren-Blum serves as BlueStar Indexes' EMEA representative and as Director in Israeli public companies. Mrs. Keren-Blum has more than 15 years of experience in the financial industry. Mrs. Keren-Blum served as Chief Legal Counsel at the biggest ETF issuer in Israel and as an associate at one of the largest Israeli law firms, specializing in capital markets and banks. Mrs. Keren-Blum holds an Executive LL.M (Cum Laude) from Tel-Aviv University and Berkeley University (California), LL.B and BA (Economics) from Tel-Aviv University.
Ilan Hadar is the Chief Financial Officer, of Foamix Pharmaceuticals Ltd., since February 2014 and also Israel Country Manager since July 2017. Mr. Hadar has over 20 years of experience in executive financial positions, previously holding positions as Finance Director of the Israeli subsidiary of Pfizer from 2011 to 2013, as Finance Manager, Accounting and Reporting, at the Israeli subsidiary of HP from 2007 to 2011, and, prior to that, as Finance Director of the Israeli subsidiary of BAE Systems. Mr. Hadar holds a BA in business administration and economics, and an MBA from The Hebrew University of Jerusalem.
Advocate Ziv Ironi- Founder & owner of Ziv Ironi, Advocates & Notary Law Firm a boutique law firm located in Tel Aviv. Mr. Ironi has over 30 years of experience as a legal counselor specializing in the fields of corporate law, tenders law, contract law, labor law and land law. Mr. Ironi has served as a director for Otsar Mifalei Yam Ltd. and is currently serving as an active director of various companies, including and Arkia’s air lines Ltd. He served as an external director of Ultra Equity Ltd and as chairman of the board of Sport Palaces Ltd. Mr. Ironi is also a member of the Board of Trustees of the Tel Aviv Museum of Art. Ziv Ironi holds a Bachelor's degree (LL.B.) from Tel Aviv University, and holds a Master's degree (LL.M.) in Commercial Law from Tel Aviv University.
Mr Samuel serves as CEO since 1997 of Adomasante who recently acquired Darmian, another company specialized in medical services for the elderly populations in France. He also leads a consulting activity in geriatric care management since 2001 for leading operators and brands in medical hardware (Hartmann), nursing homes (Korian), Telco operators (Orange Healthcare) and care insurance (Mederic Malakoff). Mr Samuel is a graduate of the EM Lyon Business School and from Lille’s Health Engineers school.